A Public Offering Undercut This Biotech Stock's Promising Cancer Data

A Public Offering Undercut This Biotech Stock's Promising Cancer Data

Iovance unveiled promising test results for a cancer treatment, but IOVA stock tumbled Thursday on a subsequent public offering. Proceeds will be used, in part, to launch the drug.